dr bennett's semaglutide FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease Dr. Sabrina Bennett, MD, Lombard,

The underlying reason is that, in the case of parenteral presentations, the effective doses of GLT-1 receptor agonists necessary for weight control are greater than those needed for glycemic control

Finan B

Royer, A

Best Compounding Pharmacies for Semaglutide: A Comprehensive Review Semaglutide, a powerful GLP-1 receptor agonist, has become a key treatment for type 2 diabetes and weight management

Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT/-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis

Researchers found that the GLP-1 group did not have higher rates of gestational diabetes, severe maternal morbidity, or other adverse maternal outcomes, suggesting that the medication may have helped mitigate elevated risk factors